

ESMO PRECEPTORSHIP PROGRAMME

PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
15-16 October 2020

CO-CHAIRS: Karim Fizazi, France
Silke Gillessen, Switzerland

SPEAKERS: Gert Attard, United Kingdom
Eva Comperat, France
Theo M. de Reijke, Netherlands
Valérie Fonteyne, Belgium
Anne-Laure Giraudet, France

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

Thursday, 15 October 2020

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR
09:15-10:35 80'	SESSION 1 Screening, diagnosis and staging	Chairs: Eva Comperat, FR Valérie Fonteyne, BE
15'	PSA screening, diagnosis and staging classification	Theo M. de Reijke, NL
20'	Pathology and molecular classification for the clinician	Eva Comperat, FR
20'	Role of PET for staging, detecting relapses and assessing response to systemic treatment	Anne-Laure Giraudet, FR
10'	Discussion	Faculty
15'	Participant clinical case discussion (1x15')	Faculty
10:35-11:05	Coffee break	

11:05-12:30 85'	SESSION 2 Localized prostate cancer	Chairs: Gert Attard, UK Eva Comperat, FR
15'	Active surveillance	Theo M. de Reijke, NL
20'	Role of brachytherapy and radiotherapy and combination with ADT	Valérie Fonteyne, BE
20'	Role of surgery and other local treatments (cryo, HiFu)	Theo M. de Reijke, NL
30'	Participants clinical case discussion (2x15')	Faculty
12:30-13:30	Lunch	
13:30-15:00 90'	SESSION 3 Locally-advanced prostate cancer	Chairs: Silke Gillesen, CH Karim Fizazi, FR
5'	Case presentation with high-risk localized prostate cancer	Karim Fizazi, FR
10'	What evidence for local treatments and which one?	Theo M. de Reijke, NL
10'	What evidence for systemic treatments and which one?	Karim Fizazi, FR
5'	Case presentation of a patient with cN1	Karim Fizazi, FR
10'	What evidence for local treatments and which one?	Valérie Fonteyne, BE
10'	What evidence for systemic treatments and which one?	Silke Gillesen, CH
10'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
15:00-15:30	Coffee break	
15:30-17:50 140'	SESSION 4 Systemic therapy	Chairs: Valérie Fonteyne, BE Karim Fizazi, FR
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillesen, CH
20'	Bone health agents, mechanism of action, efficacy and toxicities	Karim Fizazi, FR
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Gert Attard, UK
16:30-16:45	Short Coffee break	
15'	Predictive biomarkers	Gert Attard, UK
20'	Immunotherapy and other new drug targets (including DNA repair, PSMA-directed therapy)	Karim Fizazi, FR
30'	Participants clinical case discussion (2x15')	Faculty
19:00	Dinner	

Friday, 16 October 2020

09:00-10:30 90'	SESSION 5 Advanced prostate cancer	Chairs: Gert Attard, UK Theo M. de Reijke, NL
20'	Rising PSA and detectable PSA after radical local treatment: Prognosis, indications for salvage local treatments, use of early vs deferred systemic treatments	Valérie Fonteyne, BE
20'	M0 CRPC: Prognosis and treatments	Karim Fizazi, FR
20'	Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Silke Gillesen, CH
30'	Participants clinical case discussion (2x15')	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 6 Metastatic disease	Chairs: Silke Gillesen, CH Theo M. de Reijke, NL
15'	Oligo-metastatic treatment: what treatment?	Valérie Fonteyne, BE
30'	Metastatic CRPC: Current treatment	Gert Attard, UK
15'	Discussion: Sequencing of treatments	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
12:30-12:45 15'	Conclusion and farewell	
12:45-13:45	Lunch	

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion